Paspigioni CRO
Full-service CRO · Phases I–IV

Clinical research,
precisely executed.

We run trials and medical device studies across the UK, Central & Eastern Europe and Asia — pairing medical insight with operational rigour to accelerate enrolment without loosening a single control.

Explore capabilities Talk to us
hero image — site team / lab, 4:5
detail shot, 1:1
21
countries covered
I–IV
trial phases run
Oncology
& rare disease focus
Physician
founded & led
Diana Matiashvili, Founder
Diana Matiashvili
CEO & Founder
01 — Our philosophy

A strategic partner, not a vendor.

Paspigioni was founded by a medical doctor with one conviction: trial decisions should be guided by evidence and clinical judgement together. That shapes how we scope feasibility, recruit patients and defend data — competence first, documentation that stands up to inspection, timelines that hold.

Medical insight
Protocol and safety calls made by clinicians, not coordinators.
Emerging-market reach
Georgia, Ukraine, Armenia and Uzbekistan sites we know by name.
Accelerated enrolment
High-recruitment indications, realistic per-site projections.
Audit-ready by default
Compliant documentation from first submission to lock.
Member of BIA · BioIndustry Association EUCROF · European CRO Federation BioPartner UK
02 — Leadership

The people accountable
for your study.

Physicians, operations leads and regulatory specialists — one named owner per workstream, no handoff to an anonymous pool.

Diana, MD
Diana Matiashvili, MD
CEO & Founder

A medical doctor who pairs clinical expertise with an ethics-first view of research, leading international teams to a reputation for reliability and operational excellence.

Vitaly Nevinsky
Vitaly Nevinsky
Director of Operations

Physician with 20+ years leading global clinical operations across CEE and the Middle East — vendor governance and inspection readiness.

Tamar, MD
Tamar Tavberidze, MD
Director of Clinical Operations

A decade of oncological practice plus ten years of research leadership — CRA, project manager and sub-investigator, so every phase from start-up to close-out is familiar ground.

Nina
Nina Biblaia
Marketing Director

Drives global brand growth and go-to-market strategy, with a background at EY and Ciklum across clinical research and health technology.

Ilona
Ilona Bendeliana
Regulatory Manager

Manages international submissions and compliance across oncology, pulmonology and cardiology — the direct line to ethics committees and authorities.

03 — Capabilities

Everything a study needs,
under one accountability.

Request a scoped proposal →
01

Full-service trials

Feasibility and site selection, CA/EC submissions, contracts, eCRF design and validation, monitoring, EDC and data management through database lock.

Phases I–IV · device studies
02

Bioequivalence studies

Complete BE support from protocol and study planning to final analysis and regulatory submission, with audit-ready documentation at every step.

Protocol → submission
03

Pharmacovigilance

Safety reporting, aggregate assessments, PSURs, Risk Management Plans and ongoing benefit–risk evaluation with prompt signal detection.

Medical monitoring
04

Clinical logistics

Investigational product delivery, import/export coordination, temperature-controlled storage and distribution, inventory and central lab services.

Supply chain
05

Certified translation

Informed consent, patient materials, protocols and regulatory documents translated with linguistic and cultural accuracy, on tight deadlines.

In-house team
06

Medical writing

Content and language tailored to your objectives and regulatory targets — technically accurate, compliant and genuinely persuasive documentation.

Regulatory-ready
Operating footprint United Kingdom Georgia Ukraine Armenia Uzbekistan + CEE & Asia
04 — Expertise

A wide therapeutic map,
oncology at the centre.

A decade of phase I–IV work in pharmaceuticals and medical devices built an unusually broad base — and one clear specialism at its core.

01 — Core specialism

Oncology

Deep knowledge and long experience in cancer studies — often in the most challenging indications. For sponsors in oncology drug development that depth is the difference between a plan and an enrolled trial.

Discuss an oncology study
10+
years in oncology trials
I–IV
phases managed
360°
CRA, PM & sub-investigator view
11
therapeutic areas run
Also running
02 Gastroenterology
03 Endocrinology
04 Neurology
05 Pulmonology
06 Tuberculosis
07 Infectious disease
08 Dermatology
09 Otorhinolaryngology
10 Medical devices
11 Food supplements
05 — Sponsor feedback

What partners say.

“The entire Clinical Operations team has proven to be highly responsive and compliant, providing effective and timely support throughout the project — smooth, professional and solution-oriented.”

Clinical Project Manager · Opis

“Regulatory support and monitoring were always performed with great attention to detail, within agreed timelines. What stands out is responsiveness, proactive communication and a strong sense of ownership.”

Project Manager · Ergomed

“Enrolment goals were met at the assigned sites and documentation quality remained strong. Paspigioni would very likely be our partner of choice for future opportunities in Georgia.”

Senior Clinical Project Manager · Confidence Pharmaceutical Research
06 — Insights

Whitepapers, webinars
and where to find us.

All resources →
Whitepaper · May 2026

The next wave of Duchenne trials

Five-plus BLA submissions are expected in 2026. The bottleneck is not the science — it is sites. The case for Armenia, Georgia, Ukraine and Uzbekistan: 75M people, 1,400+ modelled DMD patients, largely treatment-naïve.

Read more →
Article · May 2026

Stem cell therapies: from promise to clinical reality

The shifting regulatory landscape, the operational complexity of cellular trials, and why emerging research hubs such as Georgia are becoming vital to this therapeutic shift.

Read more →
Event · June 2026

Paspigioni joins BIO International Convention 2026

22–25 June, San Diego. The world's largest biotechnology event brings together 20,000+ industry leaders from 70+ countries — find us there.

Read more →
07 — Start a conversation

Tell us about
your study.

Send a synopsis and we will come back with a feasibility view, indicative timelines and a costed proposal.

info@paspigioni.com 56 Farm Road, London N21 3JA, United Kingdom
Tbilisi, Georgia — regional operations hub
Newsletter
LinkedIn EUCROF Careers Privacy
© Paspigioni 2026 · Full-service CRO